Goldman Sachs Downgrades American Renal Associates (ARA) to Sell
- Wall Street flat as countdown to Trump's swearing-in begins
- Netflix, Inc. (NFLX) Tops Q4 EPS by 1c; Subs Beat Views
- Apple (AAPL) PT Raised to $140 at BofA/Merrill Lynch; iPhone 8 Will be 'Super-Long' Cycle
- Morgan Stanley Upgrades Tesla Motors (TSLA) to Overweight
- CP's (CP) Outgoing CEO Hunter Harrison, Activist Paul Hilal Said Set to Target CSX Corp. (CSX)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Goldman Sachs downgraded American Renal Associates (NYSE: ARA) from Neutral to Sell with a price target of $22.
Shares of American Renal Associates closed at $24.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Host Hotels (HST) to Sell
- Goldman Sachs Downgrades Dollar Tree (DLTR) to Buy
- Jefferies Downgrades Autoliv, Inc. (ALV) to Hold
Create E-mail Alert Related CategoriesDowngrades
Related EntitiesGoldman Sachs
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!